	Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan - PR Newswire
	Jefferies raises Kissei stock rating to Buy, price target to JPY5,000 - Investing.com
	US-based Rigel inks $162.5 M oncology deal with Kissei for Japan, Korea and Taiwan markets - BioSpectrum Asia
	Mitsubishi Tanabe Pharma enters into a sub-licensing agreement for oral spleen tyrosine inhibitor fostamatinib in Taiwan with Kissei Pharmaceutical - Indian Pharma Post
	Kissei Pharmaceutical discovers new TSHR antagonists - BioWorld MedTech
	Firm Represents CG Oncology in Agreement with Kissei Pharmaceutical - Wilson Sonsini
	JW Pharm acquires rights for Kissei Pharmaceutical's uterine fibroid treatment - koreabiomed.com
	Central Research Laboratories